Can you take Carvykti while pregnant or breastfeeding?

Medical-topic heads-up: This article is educational, not personal medical advice. Carvykti is a highly specialized therapy given in certified centers, so your oncology team (and often a maternal-fetal medicine specialist, if pregnancy is involved) should make the final call for your situation.

The quick (and honest) answer

Carvykti isn’t recommended during pregnancy, and there isn’t clear data to prove it’s safe while breastfeeding. That may sound like a buzzkill, but it’s the kind of “no-nonsense” guidance you actually want when the medication in question is a custom-made, living-cell therapy designed to hunt down cancer cells.

If you’re pregnant, trying to become pregnant, or nursing, the decision is less “Can I?” and more “How do we protect the baby while treating a serious cancerwithout guessing?” The safest path is usually to avoid Carvykti during pregnancy, and to avoid breastfeeding during Carvykti treatment unless your care team provides a specific plan.

What Carvykti is (and why pregnancy/breastfeeding questions get complicated fast)

Carvykti (ciltacabtagene autoleucel) is a type of CAR-T cell therapy used for multiple myeloma. Unlike most drugs that come in a bottle and politely exit your body on schedule, CAR-T is made from your own immune cells. Those cells are collected, engineered to recognize a target on myeloma cells (BCMA), and then infused back into you to do their job.

Why that matters for pregnancy and breastfeeding

• It’s a living therapy. The infused cells can persist in the body, which makes it harder to predict exposure timing for a fetus or nursing infant.
• There’s a pre-treatment chemo step. Before you get Carvykti, you typically receive “lymphodepleting” chemotherapy to prepare your immune system for the CAR-T cells. Many chemo drugs are known to be unsafe in pregnancy and breastfeeding.
• Side effects can be intense. CAR-T therapies can cause serious immune reactions (like cytokine release syndrome) and neurologic effects. Even if a fetus or infant isn’t directly exposed, severe maternal illness can affect pregnancy and postpartum recovery.

Carvykti and pregnancy: what the evidence actually says

Here’s the key point: there are no adequate human pregnancy data for Carvykti. That means no well-controlled studies in pregnant people, and no clear “this is safe” evidence. Because of that uncertaintyand because of how CAR-T worksofficial prescribing information takes a cautious stance.

Why Carvykti is not recommended during pregnancy

Carvykti’s labeling explains that it’s not known whether the CAR-T cells could cross the placenta. But based on how the therapy works, if the engineered cells did cross, they might affect the fetus’s developing immune system. Specifically, the concern includes the possibility of B-cell lymphocytopenia and hypogammaglobulinemia (lower antibody levels), which could weaken immune defenses.

Translation: Carvykti is a very intentional immune “reprogramming” therapy. A developing fetus is also building an immune system. Putting those two processes in the same room without data is… not ideal.

Pregnancy testing and timing

If you’re of reproductive potential, your team will typically verify pregnancy status before starting Carvykti. This isn’t anyone being nosyit’s basic safety planning.

What if someone becomes pregnant during the Carvykti process?

This can happen in real life because the Carvykti journey isn’t one single day. It may involve cell collection, a manufacturing period, possible “bridging” therapy, chemotherapy before infusion, and then monitoring after infusion.

If pregnancy is discovered at any point:

• Call your oncology team immediately. Don’t wait for your next appointment.
• Expect a multidisciplinary conversation. Often this includes oncology, maternal-fetal medicine, and sometimes neonatology and pharmacy specialists.
• Don’t make abrupt medication changes on your own. The plan depends on where you are in the treatment timeline and what therapies you’ve already received.

Sometimes the safest approach may be delaying certain steps; sometimes the cancer situation doesn’t allow much flexibility. Either way, this is a “team sport” decision.

Carvykti and breastfeeding: “no data” doesn’t mean “go for it”

Breastfeeding guidance is also limited because there’s no clear information on whether Carvykti is present in human milk, what it might do to a breastfed infant, or whether it affects milk production.

Why breastfeeding is usually avoided during Carvykti treatment

Even if we set Carvykti itself aside for a second, the larger treatment context matters:

• Lymphodepleting chemotherapy is typically part of the protocol, and many chemotherapy agents can enter breast milk and may harm a nursing infant.
• Supportive medications may be needed to manage side effects (fevers, infections, immune complications). Some of these medications may also be incompatible with breastfeeding depending on dose and timing.
• Infection risk and immune recovery can be a big concern after CAR-T. Even if milk exposure were a non-issue, you may be advised to limit certain exposures while your immune system recovers.

When can you restart breastfeeding after Carvykti?

Carvykti labeling doesn’t give a one-size-fits-all “you can breastfeed again after X days” timeline. That’s frustrating, but also honest. The answer depends on things like:

• Which chemo drugs you received and when
• Whether you needed additional medicines for complications
• Your immune recovery and overall clinical stability
• Your baby’s age, health status, and feeding options

In practice, many patients are advised to pause breastfeeding and use alternatives (stored milk if available, donor milk, or formula) until the oncology team and a pediatrician agree it’s safe to resume.

Birth control and family planning around Carvykti

If you’re hearing “not recommended in pregnancy,” the next logical question is: “Okay, so what do I do about contraception?” Great questionbecause planning matters here.

Contraception: what the label says (and what trials did)

Carvykti’s prescribing information notes there are insufficient data to recommend an exact duration of contraception after treatment. That’s the official “we don’t have enough evidence to be precise” statement.

However, in clinical trials:

• People who could become pregnant were advised to use a highly effective method of contraception.
• Male patients with partners of childbearing potential (or partners who were pregnant) were instructed to use a barrier method.
• This contraception guidance continued until one year after Carvykti infusion in the trial setting.

Also, your team will reference contraception guidance from the lymphodepleting chemotherapy used before Carvykti, since that chemo can carry its own reproductive risks.

Fertility preservation: the conversation you want before treatment starts

Carvykti is often used when multiple myeloma has already required several treatments, and those treatments can be tough on fertility. Still, if having children in the future matters to you, it’s worth raising the topic earlybefore lymphodepleting chemo and CAR-T infusion.

Depending on your timeline and health, options may include:

• Egg freezing (oocyte cryopreservation)
• Embryo freezing
• Sperm banking
• Ovarian tissue preservation (in select cases and settings)

Many cancer organizations emphasize that fertility planning works best when it’s started before treatment begins, so you’re not trying to squeeze complex decisions into an already intense medical timeline.

“But my situation is complicated…” (Yes. Let’s talk about common scenarios.)

Scenario 1: You’re pregnant and you relapse

Carvykti generally isn’t recommended in pregnancy, but cancer doesn’t always politely wait. If relapse happens during pregnancy, your team may weigh options like pregnancy-timing considerations, alternative therapies with more pregnancy experience, and the urgency of controlling the myeloma. In many cancers, systemic therapies are approached very cautiously in the first trimester, with different risk discussions later in pregnancy. Multiple myeloma adds its own complexity, so the plan must be individualized.

Scenario 2: You’re breastfeeding and myeloma treatment can’t wait

Sometimes the emotional whiplash is real: you’re caring for an infant, and suddenly you’re being told you need high-intensity therapy. Many patients in this situation discuss:

• Weaning earlier than planned (hard, but sometimes necessary)
• Working with a lactation consultant on comfort and supply changes
• Using stored milk or formula
• Focusing on bonding that isn’t tied to feeding method (because your baby still knows it’s you)

Scenario 3: You want to try for pregnancy after Carvykti

This becomes a planning conversation: remission status, immune recovery, infection risk, overall health, and your oncology team’s follow-up schedule all matter. Many people choose to involve maternal-fetal medicine early when planning a future pregnancy after intensive cancer therapyespecially if prior treatments affected heart, lungs, kidneys, or endocrine function.

Questions to bring to your oncology team (copy/paste friendly)

• Do I need a pregnancy test before each step (cell collection, chemo, infusion)?
• What contraception method do you consider “highly effective” for my situation?
• How long do you want me (and/or my partner) to use contraception after infusion?
• Which parts of the Carvykti process (chemo, supportive meds, infection risk) affect breastfeeding most?
• If I stop breastfeeding now, what support do you recommend (lactation, mental health, pediatric guidance)?
• Can I be referred to a reproductive endocrinologist or fertility preservation program quickly?
• When might it be medically reasonable to consider pregnancy after treatment?

The bottom line

Carvykti is not recommended during pregnancy, largely because there are no human pregnancy data and there’s a plausible mechanism for fetal immune effects if cells cross the placenta. Breastfeeding during Carvykti treatment is also generally avoided, especially because lymphodepleting chemotherapy and other medications may pose risks to a nursing infantand because Carvykti itself has unknown lactation exposure data.

If you’re facing these decisions, you deserve more than a shrug. Ask for a clear plan that covers contraception, fertility preservation, feeding alternatives, and emotional support. With the right team, it’s possible to protect both your treatment goals and your future family planseven if the timeline needs to change.

Real-world experiences (the human side of “Can I take Carvykti while pregnant or breastfeeding?”)

Clinical labels and guidelines are essential, but they don’t capture the lived experience of navigating cancer treatment and family planning at the same time. The stories below are composite experiences based on common themes patients and caregivers describe in oncology settingsshared here to help you feel less alone and more prepared for the conversations ahead.

Experience #1: “I wasn’t trying to get pregnant… but I wasn’t not trying either.”

One of the most common surprises is how quickly “casual family planning” becomes “high-stakes logistics.” People often say they assumed pregnancy wasn’t likely because of prior treatments, irregular cycles, or sheer exhaustion. Then Carvykti enters the chat, and suddenly contraception becomes a top agenda item. Many patients describe feeling awkward bringing it upuntil they realize the care team is relieved someone asked. In these conversations, patients often appreciate very concrete guidance: which contraception methods count as “highly effective,” what to do about partner contraception, and how long to keep protection in place after infusion.

Experience #2: The fertility consult that felt scary… and then empowering

When fertility preservation is an option, patients frequently describe the first appointment as emotionally heavy. It can feel unfair to discuss egg freezing or sperm banking while also dealing with relapse anxiety. But many people report that the consult ultimately gave them something cancer often steals: a sense of control. Even if they didn’t move forward with preservation, learning the options (and the timelines) helped them make peace with the plan. Some chose embryo or egg freezing before lymphodepleting chemotherapy; others decided it wasn’t feasible and focused on other future-building choices like adoption or surrogacy later. The “best” decision was the one that fit their medical urgency and personal valuesnot a perfect Instagram storyline.

Experience #3: Breastfeeding grief is real (and it deserves respect)

For postpartum patients, being told to stop breastfeeding can feel like losing a second battle on top of cancer. People describe guilt, sadness, and sometimes angerespecially if breastfeeding was going well or felt like their one “normal” thing. Practical support helps: a lactation consultant can guide comfort measures, gradual weaning (when possible), or pumping strategies for relief. Emotional support matters too: many patients find it validating when clinicians say out loud, “It makes sense that you’re grieving this.” Families often discover that bonding isn’t tied to breast milk aloneskin-to-skin contact, bottle-feeding cuddles, bedtime routines, and simply being present can carry just as much attachment magic.

Experience #4: “After Carvykti, I wanted a babybut I also wanted my body back.”

Patients who hope for pregnancy after Carvykti often describe a shift from urgency to patience. First comes recovery: regaining strength, monitoring labs, managing infection risk, and mentally processing a high-intensity therapy. Many people report that their “future pregnancy plan” became a series of small checkpoints: stable remission, improved energy, fewer complications, and a clear follow-up roadmap. Some involve maternal-fetal medicine early to discuss risks and timing; others wait until they feel emotionally ready to talk about pregnancy without it feeling like another medical project. A common takeaway is that planning a family after cancer treatment can be possiblebut it often happens on a timeline that prioritizes safety and recovery first.